A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.
暂无分享,去创建一个
M. Loveless | D. Strayer | I. Brodsky | D. Shapiro | W. Carter | P. Cheney | D. Peterson | P. Salvato | C. Thompson | W. Elsasser
[1] A. Komaroff,et al. NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. , 1992, Annals of internal medicine.
[2] R. Kikinis,et al. A Chronic Illness Characterized by Fatigue, Neurologic and Immunologic Disorders, and Active Human Herpesvirus Type 6 Infection , 1992, Annals of Internal Medicine.
[3] J. Levy,et al. Chronic fatigue syndrome: clinical condition associated with immune activation , 1991, The Lancet.
[4] M. Fletcher,et al. Immunologic abnormalities in chronic fatigue syndrome , 1990, Journal of clinical microbiology.
[5] S. Wessely. Old wine in new bottles: neurasthenia and ‘ME’ , 1990, Psychological Medicine.
[6] James F. Jones,et al. Chronic fatigue syndrome: a working case definition. , 1988, Annals of internal medicine.
[7] M. Caligiuri,et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. , 1987, Journal of immunology.
[8] R. Davey,et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. , 1985, Annals of internal medicine.